MedPlanner

MedPlanner offers the first all-in-one clinical app to manage patients. A platform that facilitates collaboration across clinicians throughout the world to overcome problems faced by the current healthcare communication by using ground-breaking app to improve patient care.

Campaign Closed RM 1,000,000 raised

125% of target	0 days left
Investors	1
Min Target	RM 800,000
Max Target	RM 1,500,000

First-Mover Deal !

Within the first 30 days of the fundraising campaign and/or upon the campaign reaching 25% of its funding target, MedPlanner will reward investors with 10% additional shares from the promoters for all individual investments of RM1,255 and above.

Introduction

What We Do

The Challenge

Medplanner is solving the problems of healthcare inefficiency arising from poor communication. At the heart of medical provision is team collaboration. Unfortunately, there is no good clinical communication system available. As the result, the impact of poor communication in healthcare can be seen as follows:

Patients

80% of medical mistakes and delayed treatments

Clinicians

60% of medical malpractice

Medical Establishments

Annual wastage from efficiencies; MYR 75 million in Malaysia

On daily basis, clinicians had to put up with :

Use of Whatsapp or similar chat apps

insecure for protected health information (PDPA 2010)
unable to conduct simultaneous/multiple case discussion risking mistakes
auto-download of images can jeopardize career

Archaic patient management structure

delays patient care for multiple teams
clinical tasks confined to writing on papers risk loss of information
difficulties in tracking patient journey because doctors are mobile

Delays in receiving clinical updates and information

long process from information released by Ministry of Health
notices from medical directors are not directly received
evidence based medicine is poorly cascaded

_{Reference :}

_{Wanted: a WhatsApp alternative for clinicians, British Medical Journal, February 2018}
_{Joint Commission Centre for Transforming Healthcare, June 2012}
_{Patient Safety America (PSA), Journal of Patient Safety, September 2013, A new evidence-based estimate of Patient Harms Associated with Hospital Care}
_{Health IT Outcomes, February 2016, Malpractice risks in miscommunication}
_{Journal of Healthcare Management, July 2010, Quantifying the economic impact of communication inefficiencies in US hospitals}
_{D4.org, September 2010, Inefficient Communication: a £1bn+ problems for NHS hospitals in England}
_{Mobile medical apps, lobbying in the USA, July 2013, D4.org}

Our Solution

Our MedPlanner app provides the following solutions :

Security & Compliance

Secure access and cloud storage
Fully encrypted to industry standard and use of blockchain technology
Capture previously unrecorded information
Audit trail of communication

All-in-one Patient Management Tool

Multiple and organised concurrent case discussions
Easy sharing of results and clinical tasking
Tracking patients’ journey
Referral and handover of patients

Clinical Bulletin

Urgent notices can be received directly by clinicians
Regular health announcement will not be missed
New guidelines on treatments can be received quickly
Able to share knowledge and discuss clinical subjects

Why Are We Different

We are the first all-in-one and comprehensive clinical app to manage patients, built from user feedback.
First to fill market gaps in Southeast Asia.
First to incorporate bulletin feature in a clinical messaging app to cascade information from health authorities, organisations and professional bodies.
Medplanner is a second-generation app built from 10 years of research and data collected from early users in the UK.
Our UI (User Interface) is truly clinical, sophisticated and relevant for healthcare users, but cleverly designed for ease of use.
Our UX (User Experience) comes with augmented tagging and AI (Artificial Intelligence) features to enable speedy patient management and to lower the risk of wrong information.

Our Revenue Model

Our Market Opportunity

Our Strategy

Our growth strategy has core elements which will primarily drive user numbers:

Organic Growth
Stimulation of Brand Awareness
Geographical Expansion

ORGANIC GROWTH
Our most responsive revenue needle comes from organic growth that comes from user invitations into Medplanner. Owing to the virality design of our chat app, we project that organic user acquisition via user-to-user invitations will be grow between 20% to 30% new per month at a deceearsing rate in the first 2 years in a new market.

BRANDING
Medplanner’s brand personality is shows competence and reliability of our service. We leverage ion the strengths of influencers, usually lead doctors in their areas of expertise or in the or workplace to help us advocate the usage of our app. To date, several doctors from various hospitals who have used our earlier version Hailadoc have expressed their interest in implementing Medplanner as their new patient management tool.

Target Users

Doctor

Nurses

Indicative Usage of Funds

We are raising funds for the purpose of further product development and marketing activities. We plan to expand our current headcount of 4 team members to 9 people in 2019 to help facilitate our growth plan.

Road Map

road

The Team

Dr Ezam Mat Ali

Co-Founder & CEO

Ahmad Fauzi

Co-Founder & CTO

Danil Dahlan

Co-Founder & CGO

Term Sheet

Issuer: Medplanner Sdn Bhd, a private limited company incorporated in Malaysia, a private limited company incorporated in Malaysia

Type of Equity: Ordinary Shares (“Shares”)

Fund Raising Period: 90 days

Pre Money Valuation: RM12,550,000

Minimum Fundraising Target: RM 800,000

Maximum Fundraising Target: RM 1,500,000

Price per Share: RM 125.50

Minimum Equity Offered: 5.99

Maximum Equity Offered: 10.68

Minimum Shares Offered: 6375

Maximum Shares Offered: 11952

Minimum Investment Amount: RM 1,255

Rewards

Eligibility

Reward(s)

Investors will receive additional 10% shares* of the investment made

Investment made within 30 days after the launch Date and/or upon the campaign reaching 25 % of its funding target; whichever occurs first.
Minimum investment amount of RM 1,255 and any amount that falls within the specified tiers.

*these are shares to be subscribed for and paid by the promoters i.e. the existing shareholders of Medplanner Sdn Bhd

Tier 1

Investment Amount

RM 1,255 to RM 5,000

Reward(s)

Investors will receive additional 10% shares* of the investment made

Tier 2

Investment Amount

RM 6,000 to RM 10,000

Reward(s)

Investors will receive additional 10% shares* of the investment made

Tier 3

Investment Amount

RM 15,000 to RM 30,000

Reward(s)

Investors will receive additional 10% shares* of the investment made

Tier 4

Investment Amount

RM 50,000 to RM 200,000

Reward(s)

Investors will receive additional 10% shares* of the investment made

Tier 5

Investment Amount

RM 300,000 to RM 1,000,000

Reward(s)

Investors will receive additional 10% shares* of the investment made

Tier 6

Investment Amount

RM 1,500,000

Reward(s)

Investors will receive additional 10% shares* of the investment made

Impact on Shareholding Structure Upon Completion of the Offering: 10% Additional Shares Reward

These are shares to be subscribed for and paid by the promoters i.e. the existing shareholders of Medplanner Sdn Bhd and therefore will not have impact on the valuation and any other matters pertaining to the shares offered.

Investor Eligibility: Angel, Sophisticated, and/or Institutional Investors, subject to the applicable investment limits prescribed under the Securities Commission’s Guidelines on Recognised Markets.

Pre Emptive Rights

Type of Shares

Information: Issuer to provide additional information upon request

Closing Period: 14 working days after the end of the Fundraising Period.

Use of Proceeds: The proceeds are intended to be used for product and network development, branding growth and marketing as well as overhead costs. The funds will be transferred to the Issuer by the end of the Closing Date.

Subscription Procedure: An Investment Agreement to subscribe ordinary shares and subject to review if required or necessary, the procedure may be amended by the Issuer and the ECF Platform.

Disclaimer

The information, calculations and remarks expressed on this term sheet or on any other part of the platform are based on information provided, disclosed and presented by Medplanner Sdn Bhd to Ata Plus Sdn Bhd, either in part or in whole. Ata Plus disclaims responsibility for the accuracy, completeness and/or validity of these information, and hence will not be held liable for any inaccurate, inappropriate or incomplete information presented on this term sheet or on any other part of the platform subject to the following :

The financial information listed on the deal page is provided by the Issuer; which includes the financial forecasts and projections, the capitalization table, the term sheet, and management accounts.

The financial forecasts and projections have been prepared by the issuer based on assumptions that have not been reviewed and certified by an independent certified accountant for its reasonableness.

THE ISSUER agrees that; all information concerning the product, business and the assets of THE ISSUER that have been furnished to Ata Plus Sdn Bhd for the purpose of the equity crowdfunding campaign is true, complete, and accurate in all material respect and is not misleading or deceptive whether by inclusion or omission.

Should the Investor require more information, they can do so by contacting Medplanner Sdn Bhd directly at [email protected] or by clicking on the ‘CONTACT’ button on the Deals Page.

Disclosure: This issuer is referred by a 3rd party which is . Ata Plus is not associated or related to the issuer and the referral party.

Disclaimer by Securities Commission

(i) No shares will be alotted or issued based on this document after six months from the closing of the offer period

(ii) This issue, offer or invitation for the offering is a proposal not requiring authorisation of the Securities Commission under section 212(8) of the CMSA 2007

(iii) This document has not been reviewed by the Securities Commission Malaysia. The Securities Commission does not recommend nor assumes responsibility for any information including any statement, opinion or report disclosed in relation to this fund raising exercise and makes no representation as to its accuracy or completeness. The Securities Commission expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the information disclosed.

Issuer	Medplanner Sdn Bhd, a private limited company incorporated in Malaysia
Type of Equity	Ordinary Shares (“Shares”)
Fund Raising Period	90 days
Pre Money Valuation	RM12,550,000
Minimum Fundraising Target	RM 800,000
Maximum Fundraising Target	RM 1,500,000
Price per Share	RM 125.50
Minimum Equity Offered	5.99
Maximum Equity Offered	10.68
Minimum Shares Offered	6375
Maximum Shares Offered	11952
Minimum Investment Amount	RM 1,255
Rewards	Eligibility Reward(s) Investors will receive additional 10% shares* of the investment made Investment made within 30 days after the launch Date and/or upon the campaign reaching 25 % of its funding target; whichever occurs first. Minimum investment amount of RM 1,255 and any amount that falls within the specified tiers. these are shares to be subscribed for and paid by the promoters i.e. the existing shareholders of Medplanner Sdn Bhd Tier 1 Investment Amount RM 1,255 to RM 5,000 Reward(s) Investors will receive additional 10% shares of the investment made Tier 2 Investment Amount RM 6,000 to RM 10,000 Reward(s) Investors will receive additional 10% shares* of the investment made Tier 3 Investment Amount RM 15,000 to RM 30,000 Reward(s) Investors will receive additional 10% shares* of the investment made Tier 4 Investment Amount RM 50,000 to RM 200,000 Reward(s) Investors will receive additional 10% shares* of the investment made Tier 5 Investment Amount RM 300,000 to RM 1,000,000 Reward(s) Investors will receive additional 10% shares* of the investment made Tier 6 Investment Amount RM 1,500,000 Reward(s) Investors will receive additional 10% shares* of the investment made
Investor Eligibility	Angel, Sophisticated, and/or Institutional Investors, subject to the applicable investment limits prescribed under the Securities Commission’s Guidelines on Recognised Markets.
Information	Issuer to provide additional information upon request
Information	N/A
Closing Period	14 working days after the end of the Fundraising Period.
Use of Proceeds	The proceeds are intended to be used for product and network development, branding growth and marketing as well as overhead costs. The funds will be transferred to the Issuer by the end of the Closing Date.
Subscription Procedure	An Investment Agreement to subscribe ordinary shares and subject to review if required or necessary, the procedure may be amended by the Issuer and the ECF Platform.
Disclaimer	The information, calculations and remarks expressed on this term sheet or on any other part of the platform are based on information provided, disclosed and presented by Medplanner Sdn Bhd to Ata Plus Sdn Bhd, either in part or in whole. Ata Plus disclaims responsibility for the accuracy, completeness and/or validity of these information, and hence will not be held liable for any inaccurate, inappropriate or incomplete information presented on this term sheet or on any other part of the platform subject to the following : The financial information listed on the deal page is provided by the Issuer; which includes the financial forecasts and projections, the capitalization table, the term sheet, and management accounts. The financial forecasts and projections have been prepared by the issuer based on assumptions that have not been reviewed and certified by an independent certified accountant for its reasonableness. THE ISSUER agrees that; all information concerning the product, business and the assets of THE ISSUER that have been furnished to Ata Plus Sdn Bhd for the purpose of the equity crowdfunding campaign is true, complete, and accurate in all material respect and is not misleading or deceptive whether by inclusion or omission. Should the Investor require more information, they can do so by contacting Medplanner Sdn Bhd directly at [email protected] or by clicking on the ‘CONTACT’ button on the Deals Page.
Disclaimer by Securities Commission	(i) No shares will be alotted or issued based on this document after six months from the closing of the offer period (ii) This issue, offer or invitation for the offering is a proposal not requiring authorisation of the Securities Commission under section 212(8) of the CMSA 2007 (iii) This document has not been reviewed by the Securities Commission Malaysia. The Securities Commission does not recommend nor assumes responsibility for any information including any statement, opinion or report disclosed in relation to this fund raising exercise and makes no representation as to its accuracy or completeness. The Securities Commission expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the information disclosed.

Risk Disclaimer

Investing in equity crowdfunding involves certain risks that include uncertainty of returns, lack of liquidity, dilution, material events and lack of control. Investments should be done as part of a diversiﬁed portfolio. ATA PLUS offers investment opportunities to investors who understands these risks in making their own investment decisions.

PLEASE READ THE FULL RISK WARNING BEFORE DECIDING TO INVEST.

This page is approved as a ﬁnancial promotion by ATA PLUS Sdn. Bhd., which is authorized and regulated by the Security Commission of Malaysia. Deals that are up for investment are only offered to members of ata-plus.com on the basis of information provided by the companies concerned. ATA PLUS takes no responsibility for this information or for any recommendations or opinions made by the companies. For further information on this, please read our Term of Use.

MedPlanner

Introduction

What We Do

The Challenge

Our Solution

Why Are We Different

Our Revenue Model

Our Market Opportunity

Our Strategy

Target Users

Indicative Usage of Funds

Road Map

The Team

Dr Ezam Mat Ali

Co-Founder & CEO

Ahmad Fauzi

Co-Founder & CTO

Danil Dahlan

Co-Founder & CGO

Term Sheet

Register your interest here!

Please enter your details below

Risk Disclaimer